盐皮质激素与AT1受体拮抗剂对原发性醛固酮增多症醛固酮-肾素比值的影响——EMIRA研究
本研究在确诊原发性醛固酮增多症(PA)的患者中,观察坎利酮单药及坎利酮联合奥美沙坦治疗对醛固酮/肾素比值(ARR)的影响。结果显示坎利酮未降低血浆醛固酮或升高肾素,高ARR及真阳性率不受影响;加用奥美沙坦后肾素升高、醛固酮轻度降低,ARR降低且假阴性率增加。
要点
- 坎利酮单药不降低醛固酮、不升高肾素,高ARR及真阳性率不受影响。
- 加用奥美沙坦后肾素升高、醛固酮轻度降低,ARR降低且假阴性率增加。
- 在有效控制血钾和血压的剂量下,MRA似不危及PA诊断准确性。
核心结论
- 在有效控制血钾和血压的剂量下,坎利酮不妨碍PA的准确诊断,加用奥美沙坦轻度增加假阴性率,MRA似不危及PA诊断准确性。
研究设计与样本
- 患者自身对照研究,连续纳入经肾上腺静脉取血分型且确诊PA的患者。
主要发现
- 坎利酮未降低血浆醛固酮也未升高肾素,高ARR和真阳性率保持不变。
- 加用奥美沙坦后肾素升高、醛固酮轻度降低,ARR降低且假阴性率增加。
关键数值与推荐
- 坎利酮50-100 mg口服治疗1个月,随后加用奥美沙坦10-20 mg口服治疗1个月,前2周上调剂量至血压和低钾血症控制。
- 单侧PA患者行肾上腺切除术,双侧PA患者接受药物治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: While current guidelines recommend the withdrawal of mineralocorticoid receptor antagonist (MRA) and renin-angiotensin system blockers for the screening and detection of primary aldosteronism (PA), this can worsen hypokalemia and control of high blood pressure (BP) values. OBJECTIVE: To investigate whether aldosterone/renin ratio (ARR) values were affected by the MRA canrenone and/or by canrenone plus olmesartan treatment in patients with PA. DESIGN: Within-patient study. SETTING: The European Society of Hypertension center of excellence at the University of Padua. PATIENTS: Consecutive patients with an unambiguous diagnosis of PA subtyped by adrenal vein sampling. INTERVENTIONS: Patients were treated for 1 month with canrenone (50-100 mg orally), and for an additional month with canrenone plus olmesartan (10-20 mg orally). Canrenone and olmesartan were up-titrated over the first 2 weeks until BP values and hypokalemia were controlled. Patients with unilateral PA were adrenalectomized; those with bilateral PA were treated medically. MAIN OUTCOME MEASURES: BP, plasma levels of sodium and potassium, renin and aldosterone. RESULTS: Canrenone neither lowered plasma aldosterone nor increased renin; thus, the high ARR and true positive rate remained unaffected. Addition of the angiotensin type 1 receptor blocker raised renin and slightly lowered aldosterone, which reduced the ARR and increased the false negative rate. CONCLUSIONS: At doses that effectively controlled serum potassium and BP values, canrenone did not preclude an accurate diagnosis in patients with PA. Addition of the angiotensin type 1 receptor blocker olmesartan slightly raised the false negative rate. Hence, MRA did not seem to endanger the accuracy of the diagnosis of PA.
引用
- Rossi GP, Ceolotto G, Rossitto G, et al. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study. J Clin Endocrinol Metab. 2020. PMID: 32067030. doi:10.1210/clinem/dgaa080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。